These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 17097964

  • 1. Conversion to sirolimus in renal transplant patients with tumors.
    Sánchez-Fructuoso A, Conesa J, Perez Flores I, Ridao N, Calvo N, Prats D, Rodríguez A, Barrientos A.
    Transplant Proc; 2006 Oct; 38(8):2451-2. PubMed ID: 17097964
    [Abstract] [Full Text] [Related]

  • 2. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V, Gutierrez C, Cabello M, Burgos D, Sola E, Gonzalez-Molina M.
    Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
    [Abstract] [Full Text] [Related]

  • 3. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Sep; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 4. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
    Ruiz JC, Diekmann F, Campistol JM, Sanchez-Fructuoso A, Rivera C, Oliver J, Fernandez-Fresnedo G, Arias M.
    Transplant Proc; 2005 Nov; 37(9):3833-5. PubMed ID: 16386555
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the efficacy and safety of conversion to sirolimus in 85 renal transplant recipients.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Gonzalez Molina M, Hernandez D.
    Transplant Proc; 2009 Nov; 41(6):2137-8. PubMed ID: 19715855
    [Abstract] [Full Text] [Related]

  • 6. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 7. Proteinuria after conversion to sirolimus in renal transplant recipients.
    Sahin GM, Sahin S, Kantarci G, Ergin H.
    Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 9. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 27; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 10. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
    Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M.
    Transplant Proc; 2007 Nov 27; 39(9):2736-9. PubMed ID: 18021973
    [Abstract] [Full Text] [Related]

  • 11. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ, González E, Andrés A, Morales JM.
    Transplant Proc; 2009 Nov 27; 41(6):2348-50. PubMed ID: 19715916
    [Abstract] [Full Text] [Related]

  • 12. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H, Froidure A, Dandavino R, Daloze P, Hébert MJ, Colette S, Boucher A.
    Transplant Proc; 2009 Oct 27; 41(8):3308-10. PubMed ID: 19857737
    [Abstract] [Full Text] [Related]

  • 13. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 14. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
    Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E.
    Liver Transpl; 2007 May 27; 13(5):658-64. PubMed ID: 17457887
    [Abstract] [Full Text] [Related]

  • 15. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 16. The effect of sirolimus in the development of chronic allograft nephropathy.
    Gürkan A, Kaçar S, Erdoğdu U, Varilsüha C, Kandemir G, Karaca C, Akman F.
    Transplant Proc; 2008 Aug 27; 40(1):114-6. PubMed ID: 18261561
    [Abstract] [Full Text] [Related]

  • 17. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov 27; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma.
    Gutiérrez-Dalmau A, Sánchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC, Iranzo P, Torregrosa JV, Oppenheimer F, Campistol JM.
    Transplant Proc; 2005 Nov 27; 37(9):3836-8. PubMed ID: 16386556
    [Abstract] [Full Text] [Related]

  • 19. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.
    Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035
    [Abstract] [Full Text] [Related]

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.